YL-202 is under clinical development by Suzhou Medilink Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YL-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YL-202 overview

YL-202 is under development for the treatment of advanced or metastatic non-small cell lung cancer and advanced or metastatic HR-positive and HER2-negative breast cancer (HER2- Breast Cancer). The drug candidate is administered through intravenous route.

Suzhou Medilink Therapeutics overview

Suzhou Medilink Therapeutics (Suzhou Medilink) is a biotech company focusing on antibody-drug conjugate research & development. Suzhou Medilink is headquartered in Suzhou, Jiangsu, China.

For a complete picture of YL-202’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.